Initiation of triple immunization program for PD-1/L1 monoclonal antibody treatment of drug-resistant prenabulin...

Transfer from Pharmaceutical Mission Hills

On June 4th, Wanchun Medicine announced that a Phase 1b/2 study of pranabulin combined with checkpoint inhibitors and radiotherapy at MD Anderson Cancer Center ushered in the first patient administration.

It is reported that this trial was initiated by researchers to evaluate the safety and tolerability of pranabulin, PD-1/PD-L1 antibody and radiotherapy triple therapy in patients with 7 types of metastatic or locally advanced cancer Sex.

Pranabrin is a selective immunomodulator that binds to microtubules.

Wanchun Medicine demonstrated the concept of triple therapy at the AACR annual meeting held in 2020.

Effectiveness study: In an animal model of breast cancer that is resistant to PD-1 antibody monotherapy, the triple I/O treatment program of Pranabrin+PD-1 antibody+radiotherapy achieved 100% complete tumor remission (CR).

Distal effect: When the anticancer effect of pranabulin triple therapy on chemotherapy-irradiated and unirradiated tumors (distal effect) was evaluated in the same mouse, the results showed a good distal effect, indicating that the systemic anticancer effect was activated.

This provides data support for the concept of triple therapy and clinical research.

Therefore, the goal of this trial is to allow those patients who developed drug resistance during PD-1/PD-L1 treatment to continue to receive the original immunotherapy, and to reverse their resistance to the original PD-1/PD-L1 through triple therapy.

Public information shows that Panabrin has completed 9 clinical trials around the world, including four phase 2 and 3 international multicenter clinical trials for neutropenia (CIN), and submitted them in China and the United States.

Note: The original text has been deleted

▽ attention [drug Mingkang Germany ] micro-channel public number